NCT04370483View on ClinicalTrials.gov

Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma

EARLY_PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

October 8, 2020

Primary Completion Date

December 16, 2025

Study Completion Date

December 16, 2025

Conditions
Smoldering Plasma Cell Myeloma
Interventions
DRUG

Leflunomide

Gievn PO

OTHER

Quality-of-Life Assessment

Ancillary studies

Trial Locations (1)

91010

City of Hope Medical Center, Duarte

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER